A fusion protein strategy for high-yield production of DOPA- modified recombinant mussel adhesive protein Pvfp-5P
This study presents a green and scalable fusion protein strategy using *Pichia pastoris* to achieve high-yield production of DOPA-modified mussel adhesive protein Pvfp-5P, which demonstrates superior wound healing promotion, versatile surface adhesion, and exceptional flexibility for biomedical applications.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Deep beneath the ocean surface, mussels cling to rocks, ship hulls, and piers with a tenacity that defies the constant battering of waves and tides. They achieve this feat not with glue in a bottle, but with a specialized protein secreted from their feet. This natural adhesive, known as mussel adhesive protein, contains a unique chemical ingredient called DOPA. This molecule acts like a molecular velcro, capable of forming strong bonds with almost any surface, whether it is wet, dry, rough, or smooth. Because of these properties, scientists have long wanted to use this protein for human medicine, hoping to create better bandages, surgical glues, or coatings for medical devices. However, harvesting enough of this protein directly from mussels is slow and inefficient, and trying to manufacture it in a lab has historically been difficult, often resulting in tiny amounts of a product that lacks the crucial chemical modification needed to work.
A team of researchers set out to solve this production problem by turning to a microscopic yeast called Pichia pastoris, a workhorse in biotechnology known for its ability to churn out large quantities of proteins. The challenge was that the yeast did not naturally produce the mussel protein well, and it lacked the internal machinery to add the essential DOPA modification. To overcome this, the scientists engineered a clever fusion strategy. They took the gene for the mussel protein and attached it to a piece of DNA that codes for a collagen-like fragment, a type of protein structure that the yeast happens to love and produce in abundance. They also introduced a second gene from a soil bacterium, which acts as a factory worker to convert the protein's tyrosine building blocks into the vital DOPA ingredient. This combined system was designed to act as a single, high-yield production line inside the yeast cell.
The results of this approach were striking. When the researchers grew the engineered yeast in standard laboratory flasks, the cells secreted the new fusion protein at a rate of approximately 300 milligrams per liter. This is a significant leap forward compared to previous attempts, which often struggled to produce even 100 milligrams per liter. The team was able to purify this protein in a single step, removing impurities to achieve a purity level greater than 90 percent. Crucially, the chemical analysis confirmed that the protein had been successfully modified, containing 2.5 percent DOPA by weight. While this is slightly less than the 3.3 percent found in naturally harvested mussel protein, it is well within the range considered effective for medical use and far superior to the unmodified versions produced by other methods.
To test if this lab-made protein actually worked, the researchers examined how it interacted with living cells and surfaces. They placed the protein on a layer of mouse fibroblast cells, which are a type of cell involved in wound healing, and watched how quickly the cells moved to close a gap. The cells treated with the new fusion protein healed the gap much faster than those treated with natural mussel protein, closing 93.5 percent of the wound in three days compared to 83.5 percent for the natural version. The protein also proved to be an excellent coating agent. When applied to glass, a very wet surface, and polystyrene, a moderately dry surface, it stuck firmly and evenly, demonstrating its ability to bond with diverse materials just like its natural counterpart.
Finally, the team measured the physical nature of the protein to understand how it would behave in the body. They found that the material is incredibly soft and flexible, with an elastic modulus of 2.34 kilopascals. This extreme softness means the protein can easily conform to the shape of a wound or a tissue surface, ensuring a tight and secure bond without being rigid or brittle. By combining a fusion strategy that boosts production with a co-expression system that adds the necessary chemical activity, the researchers have created a scalable and efficient way to make a bioactive adhesive. This work suggests a viable path forward for producing large quantities of a material that could one day improve how we treat wounds, repair tissues, and engineer medical surfaces.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.